mynth
02/2021MajorityLBO

Siparex takes majority stake in Winncare

FRANCE Life Sciences / Medical Devices EV €100–350M

Context

Siparex ETI has entered into exclusive negotiations to acquire a majority stake in Winncare, marking the first investment of its Siparex ETI 5 fund. This transaction follows a successful period of ownership by IDI, which originally took control of the group in 2014 and supported a doubling of the company,s size through international expansion. In this new capital structure, IDI is exiting its majority position but remains a minority investor, alongside the management team led by President Philippe Chêne, who continues to drive the group,s strategic vision. The primary rationale for this LBO is to provide Winncare with the financial resources to act as a "natural consolidator" in the fragmented European medical equipment market. Under Siparex,s sponsorship, the group intends to accelerate its international deployment and prioritize the roll-out of new high-tech offerings, such as connected fall-prevention systems and modernized clinical bed ranges. The deal leverages the positive demographic trends of the "Silver Economy," focusing on high-quality care for the elderly. Furthermore, the partnership is built on shared values of corporate social responsibility, with a clear objective to transition Winncare into a mission-driven enterprise (entreprise à Mission), focusing on the social impact of its healthcare solutions and the professionalization of the caregiving sector.

By taking control of Winncare, Siparex continues its expansion strategy. Previously, the group had completed 2 acquisitions, including Clayens Group in 2019.

Winncare, which reported an EBITDA margin of [members only] in 2020, is valued in this transaction at an EV/EBITDA multiple of 10x–18x.

-> Deep-dive in Healthcare & Pharma market trends

Target

Winncare is a leading European manufacturer of medical devices specifically designed for the care of individuals with loss of autonomy. The company,s product portfolio includes high-tech anti-bedsore mattresses, medicalized beds, and patient-handling solutions aimed at improving the quality of life for the elderly and those in rehabilitation. Operating with an industrial business model, Winncare supplies its essential medical equipment to nursing homes, hospitals, and home-care providers globally. Its value proposition is built on technical innovation and the reliability of its "first-necessity" products, which address the growing healthcare demands of an aging global population. The group,s strategy centers on being a consolidation platform in the specialized medical furniture market, leveraging a robust R&D pipeline to maintain regulatory compliance and clinical efficacy. By integrating digital solutions into its hardware, Winncare ensures better patient monitoring and caregiver efficiency. The company maintains a strong international presence, focusing on expanding its manufacturing and distribution footprint across Europe and North America through both organic innovation and strategic industrial acquisitions.

Ent. Value

€100–350M

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

10x–18x

EV / EBIT

10x–18x

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2020
€50–100M
€5–25M
€5–25M
2019
€50–100M
€5–25M
€5–25M

Other operations with Winncare

Other operations with Winncare
DateAcquirerTargetCountrySector
03/2026SIPAREXWINNCAREFRANCEMedical Devices
12/2021WINNCAREPHARMAOUEST INDUSTRIESFRANCEMedical Devices

Other operations with Siparex

Other operations with Siparex
DateAcquirerTargetCountrySector
10/2025SIPAREX / BPIFRANCEBRIFER (LA FERROVIAIRE DE LA BRIE)FRANCERailways
04/2025SIPAREXNOOUSFRANCERecruitment / Headhunting
03/2025SIPAREXLABORATOIRE POLIDISFRANCEMedical Consumables
07/2023SIPAREXGROUPE PASSMANFRANCEIT Equipment
05/2023SIPAREXSODIKARTFRANCECycling & Micromobility
07/2021SIPAREXALCATRAZ ITFRANCEOperators
05/2020SIPAREX / BPIFRANCEGROUPE TOP CHRONOFRANCELast Mile Delivery
08/2019SIPAREXCLAYENS GROUPFRANCEPlastics
09/2013SIPAREXMEDIASCIENCEFRANCEEducational Equipment
04/2010SIPAREX / RHÔNES-ALPES PMEGROUPE PASSMANFRANCEIT Equipment

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
04/2021DIASORINLUMINEX CORPORATIONUNITED STATESDiagnostic Equipment
03/2021CVCCOOPER-VEMEDIAFRANCEGenerics / Labs
02/2021IK PARTNERSINNOVAD GROUPBELGIUMAnimal Health
01/2021ARDIAN / BNP PARIBAS DEVELOPPEMENTPROTEORFRANCEImplants & Prosthetics
01/2021MONTAGU PRIVATE EQUITYIMV TECHNOLOGIESFRANCER&D Biotech
01/2021SAGARDNUTRISENSFRANCENutrition & Dietary Supplements
11/2020NOVALPINA CAPITALLABORATOIRE X.OFRANCEGenerics / Labs
10/2020SULZERHASELMEIERSWITZERLANDMedical Consumables
10/2020ARDIANH2 PHARMAFRANCECDMO
09/2020EQT PARTNERSSCHÜLKEGERMANYMedical Consumables

REFERENCES

Valuation range: EV €100–350M

Revenue range: €50–100M

EBITDA range: €5–25M

EV/Revenue range: 1x - 3x

EV/EBITDA range: 10x - 18x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Winncare by Siparex are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: winncare

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Winncare, a French company specialised in Medical Devices, by Siparex in 2021, structured as a leveraged buyout (LBO). Ownership has since evolved, leading to a subsequent transaction with Siparex in March 2026 (see the dedicated deal page for details).

How was the acquisition of Winncare by Siparex valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €100–350M band, its EV/EBITDA multiple within the 10x - 18x range, and its EV/revenue multiple within the 1x - 3x range. Exact figures are available to members.

What were Winncare’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Winncare generated annual revenue estimated in the €50–100M range and EBITDA in the €5–25M bracket (FY 2020). Detailed financial figures are available to members.

What sources support the information on this transaction?

Information on this transaction is sourced from the official corporate announcement published by the parties, corroborated by a private document shared by the community and verified by the mynth team to ensure the accuracy of the shared information.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.